|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,714.90 INR | +0.22% |
|
+0.62% | -0.28% |
| Capitalization | 4,10600Cr 4.52TCr 3.81TCr 3.49TCr 3.32TCr 6.15TCr 6.36TCr 40TCr 16TCr 1,97400Cr 17TCr 17TCr 6,93500Cr | P/E ratio 2026 * |
35.2x | P/E ratio 2027 * | 30.4x |
|---|---|---|---|---|---|
| Enterprise value | 3,88100Cr 4.28TCr 3.6TCr 3.3TCr 3.13TCr 5.81TCr 6.01TCr 38TCr 15TCr 1,86600Cr 16TCr 16TCr 6,55600Cr | EV / Sales 2026 * |
6.68x | EV / Sales 2027 * | 5.9x |
| Free-Float |
44.9% | Yield 2026 * |
0.86% | Yield 2027 * | 0.96% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.22% | ||
| 1 week | +0.62% | ||
| Current month | +7.50% | ||
| 1 month | -1.22% | ||
| 3 months | -0.07% | ||
| 6 months | +6.62% | ||
| Current year | -0.28% |
| 1 week | 1,684.3 |  | 1,719.8 |
| 1 month | 1,583.7 | | 1,744.3 |
| Current year | 1,583.7 | | 1,806.6 |
| 1 year | 1,548 | | 1,851.2 |
| 3 years | 922.45 | | 1,960.35 |
| 5 years | 562.1 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 57 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 73 | 25/05/2018 | |
| Director/Board Member | 70 | 21/05/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.22% | +0.62% | +0.89% | +68.91% | 4.52TCr | |
| +0.14% | +4.10% | +24.85% | +140.76% | 3.4TCr | |
| -1.47% | +0.25% | -8.47% | +30.14% | 1.2TCr | |
| +2.52% | +1.73% | -2.26% | +95.34% | 996Cr | |
| +0.43% | +0.43% | +42.68% | +121.80% | 845.83Cr | |
| +0.32% | +9.10% | +77.47% | +39.78% | 847.2Cr | |
| -0.58% | -5.38% | +179.15% | +869.58% | 818.89Cr | |
| -1.63% | +1.64% | +62.77% | -11.52% | 780.53Cr | |
| -0.56% | +3.18% | +7.74% | +47.14% | 667.6Cr | |
| +0.96% | +3.84% | +40.02% | +381.42% | 626.64Cr | |
| Average | +0.04% | +3.01% | +42.48% | +178.34% | 1.47TCr | |
| Weighted average by Cap. | +0.09% | +2.66% | +27.45% | +138.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 58TCr 640.34Cr 539.68Cr 493.94Cr 469.32Cr 870.2Cr 899.61Cr 5.7TCr 2.27TCr 28TCr 2.4TCr 2.35TCr 98TCr | 64TCr 709.09Cr 597.62Cr 546.97Cr 519.7Cr 963.62Cr 996.2Cr 6.31TCr 2.52TCr 31TCr 2.66TCr 2.6TCr 1,08700Cr |
| Net income | 12TCr 127.35Cr 107.33Cr 98Cr 93Cr 173.07Cr 178.92Cr 1.13TCr 452.31Cr 5.56TCr 477.62Cr 467.8Cr 20TCr | 14TCr 149.37Cr 125.89Cr 115.22Cr 109.48Cr 202.99Cr 209.85Cr 1.33TCr 530.51Cr 6.52TCr 560.2Cr 548.69Cr 23TCr |
| Net Debt | -22TCr -247.16Cr -208.31Cr -190.65Cr -181.15Cr -335.88Cr -347.23Cr -2.2TCr -877.81Cr -11TCr -926.94Cr -907.89Cr -38TCr | -31TCr -343.57Cr -289.56Cr -265.02Cr -251.81Cr -466.89Cr -482.68Cr -3.06TCr -1.22TCr -15TCr -1.29TCr -1.26TCr -53TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | 1,714.90 ₹ | +0.22% | 13,59,444 |
| 11/26/11 | 1,711.10 ₹ | +0.19% | 11,75,501 |
| 10/26/10 | 1,707.80 ₹ | +0.19% | 18,69,988 |
| 09/26/09 | 1,704.60 ₹ | +0.56% | 26,47,031 |
| 06/26/06 | 1,695.10 ₹ | -0.44% | 12,77,116 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition